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We also analyzed secondary graft patency in this cohort and
the findings were similar to those for primary graft patency.
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Dr Michelle Mueller (Salt Lake City, Utah). I would like to
thank the program committee for inviting me to be a discussant.
Congratulations to Dr Hiramoto on a very nice presentation and
the authors on an excellent study and paper.
Many of us have the impressing that women with peripheral
artery disease do more poorly than men. The question is why, and
can we do anything to improve their surgical outcomes. In this
prospective study, the authors show us that high-sensitivity C-
reactive protein (CRP) and fibrinogen are not only elevated in
women at baseline when compared to men, but those women with
elevated CRP or fibrinogen have decreased primary graft patency.
A few questions and comments:
In the paper you state there are no differences in the outflow
vessels (popliteal versus tibial versus pedal). However, there were
significantly more women with critical limb ischemia than men. Is
there a trend towards more infrapopliteal bypasses in women in
general, and more specifically in those with elevated inflammatory
markers?
Dr Jade S. Hiramoto. Thank you for reviewing our manu-
script and for your kind comments. Indeed, there were significantly
more womenwith critical limb ischemia in this cohort compared to
men. However, there were no significant differences in the target
outflow vessels by sex. In both men and women, about half
underwent a bypass graft to the popliteal artery, and the other half
underwent a bypass graft to either a tibial or pedal vessel. There was
no statistically significant difference, nor was there a trend toward
more infrapopliteal bypasses in women. Those patients with either
CRP 5 mg/L or fibrinogen 600 mg/dL were more likely to
undergo an infrapopliteal bypass compared to those with CRP5
mg/L or fibrinogen 600 mg/dL, but this was true for both the
men and women in this cohort.
Dr Mueller. Does the decreased primary graft patency in
women with elevated CRP or fibrinogen correlate with graft
thrombosis or limb loss, or are there just more interventions on
grafts in these groups?
Dr Hiramoto. The discussant raises an important question.
Of the 78 primary patency events, 26 (33%) were due to graft
thrombosis and 52 (67%) were revisions for graft stenosis. Both
men and women had similar profiles for loss of primary patency—
37% of the primary patency events were graft thrombosis in
women, and 31% were graft thrombosis events in men. There was
no significant difference in the type of primary patency event
(thrombosis or stenosis) based on CRP or fibrinogen values. This
was true when analyzed in the overall cohort and when separately
analyzed by sex.omen with CRP5 mg/L were significantly more likely to lose
econdary graft patency compared to women with CRP5mg/L,
nd women with fibrinogen600 mg/dL were significantly more
ikely to lose secondary graft patency compared to women with
brinogen600mg/dL. These findings were not seen in the men
n this cohort.
Dr Mueller. Would a more intensive graft surveillance pro-
ram decrease graft thrombosis and improve limb salvage?
DrHiramoto. It is difficult to know whether a more intensive
raft surveillance program would decrease the graft thrombosis
ate. Most of the losses of primary graft patency occurred within
he first year, and we performed duplex ultrasound examination of
he bypass grafts at 1, 3, 6, 9, and 12 months postoperatively.
ased on the findings in this study, one might consider increasing
he frequency of this surveillance in a higher risk patient, for
nstance, a woman with CRP 5 mg/L or fibrinogen 600
g/dL. However, it is unclear whether this would change the
verall outcome.
Dr Mueller. Finally, you recommend aggressive risk factor
odification. Would you delay bypass in women with critical limb
schemia and elevated inflammatory markers for risk factor modi-
cation, and what modifications would you recommend? With our
urrent knowledge regarding these inflammatory markers, are we
ot already encouraging smoking cessation and aggressively treat-
ng patients with statins? Perhaps we are failing to recognize
eripheral artery disease early in women and also failing to aggres-
ively medically mange them.
Dr Hiramoto. Because of the overall size of the cohort and
elatively small numbers of women, I think that one should con-
ider the findings from our study hypothesis-generating. I think it
rovides important background information for future studies to
urther evaluate this interaction between sex and inflammation.We
elieve that all at-risk individuals should stop smoking and be
reated with statins, yet 37% of our cohort were still smoking, and
0% of the women in this cohort were not on statin therapy. So,
here is still room for improvement. At this point in time, I would
ot recommend delaying bypass grafting in women with critical
imb ischemia and elevated inflammatory markers for risk factor
odification without further confirmatory data. Finally, I agree
ith Dr. Mueller—epidemiologic studies have demonstrated that
eripheral artery disease prevalence is equal (if not higher) in
omen compared to men. We are not doing a good enough job at
ecognizing peripheral artery disease early in women, and hence,
e are failing to provide the appropriate aggressive medical man-
gement.
